Recent

% | $
Quotes you view appear here for quick access.

Tessera Technologies Inc. Message Board

sts_66 66 posts  |  Last Activity: Jun 22, 2015 2:49 PM Member since: Jun 5, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    2-1 split really?

    by mdcrisis Jun 15, 2015 5:47 PM
    sts_66 sts_66 Jun 22, 2015 2:49 PM Flag

    GOOG, the "new" class C non-voting shares, diverged from the new class A stock, which is GOOGL (pretty confusing symbol swap!) - GOOG has stayed flat while GOOGL has continued up. At least the GOOG split has protection against that happening, at least for a while - shareholders get some pro-rated fraction of cash and GOOGL shares based on the price difference - did NOT see that in the UA split announcement?

    Not sure I'm going to stay in this now - stock price will be cut in half, so you'll effectively only receive 50% of future price gains in the class A stock if class C shares don't keep pace. Might be wiser to get out then rebuy new class A before the split ocurrs - and it WILL occur, since Plank has 66% of votes and he wants it to happen - onbody elee's opinion will count.

  • sts_66 sts_66 Jun 19, 2015 1:58 PM Flag

    exercising options and immediately selling the new shares is a "sale"? Huh? Ok, I kinda see your point - only one insider truly "sold":

    Fort John G. Chief Medical Officer 78,905 ***Sale on exercise at $10.93*** $862,445 48,348 direct

    The other selling was done to cover taxes for the options that were exercised.

  • Sorry the format didn't copy right - google "Openinsider" and find the site to see the trades for yourself

    SEC Form 4

    Trade Date

    Ticker

    Insider

    Title

    Shares

    Insider Trade

    Value

    Owned

    Held
    DJun 18 21:27:03

    MJun 16 2015
    POZN Fort John G. Chief Medical Officer 84,402 Option exercise at $4.72 $398,313 84,993 direct
    DJun 18 21:27:03

    MJun 16 2015
    POZN Fort John G. Chief Medical Officer 78,905 Sale on exercise at $10.93 $862,445 48,348 direct
    DJun 18 21:27:03

    Jun 16 2015
    POZN Fort John G. Chief Medical Officer 4,945 OptEx/tax payment at $10.02 $49,549 48,348 direct
    DJun 18 21:26:42

    MJun 16 2015
    POZN Hodges William L Sr. VP Finance, CFO 122,364 Option exercise at $4.61 $564,048 157,533 direct
    DJun 18 21:26:42

    MJun 16 2015
    POZN Hodges William L Sr. VP Finance, CFO 81,581 OptEx/tax payment at $10.21 $832,941 129,353 direct
    DJun 18 21:21:16

    MJun 16 2015
    POZN Thomas Gilda Marie Sr. VP, Gen Cnsl, Secretary 50,588 Option exercise at $7.12 $360,024 71,186 direct
    DJun 18 21:21:16

    MJun 16 2015
    POZN Thomas Gilda Marie Sr. VP, Gen Cnsl, Secretary 41,692 OptEx/tax payment at $10.02 $417,754 62,671 direct
    DJun 18 21:19:20

    Jun 16 2015
    POZN Barnhardt John E VP, Finance, Administration 75,304 Option exercise at $8.62 $649,120 124,433 direct
    DJun 18 21:19:20

    May 21 2014
    POZN Barnhardt John E VP, Finance, Administration 68,918 OptEx/tax payment at $10.02 $690,558 55,515 direct

  • Reply to

    Should we be concerned about Deerfield

    by streetmartianx Jun 17, 2015 10:13 PM
    sts_66 sts_66 Jun 18, 2015 11:08 AM Flag

    Deerfield is why I got out of POZN - yeah, left money on the table given the current pps, but the risk was too high to stay in IMHO. BTW, TBUFF's Fibricor CV drug is a fenofibrate, a class of drugs that has been totally disproven to reduce CV risk - sales will drop to nothing. POZN will rise or sink on Yosprala sales - still would be concerned about costs of GIA if I still held it.

  • Reply to

    2-1 split really?

    by mdcrisis Jun 15, 2015 5:47 PM
    sts_66 sts_66 Jun 17, 2015 11:34 AM Flag

    Chart GOOG and GOOGL and see if you still want to say "woohoo" - personally, I'm not sure if I like this or not - who wants to hold non-voting non-dividend paying stock that apparently won't appreciate in value?

  • Reply to

    wow

    by gkas711 Apr 27, 2015 2:16 PM
    sts_66 sts_66 Jun 11, 2015 6:04 PM Flag

    Great advice to someone owning it in an IRA.....

  • Reply to

    Thanks shortie!

    by sts_66 Jun 8, 2015 6:18 PM
    sts_66 sts_66 Jun 9, 2015 11:31 AM Flag

    Not saying it won't happen, just that I got tired of waiting for PA revenue to start coming in - and AMRN+POZN really soured me on FDA processes - POZN CRLs were just nails in the coffin. BTW, folks thought Vascepa would easily capture Lovaza market share, which was $1B, but it hasn't happened, despite being a vastly superior drug (I take it myself). Hundreds of posts were written just like yours showing potential annual revs, but it was just that, potential. POZN of course has a very different product in Yosprala, but it ain't approved yet either. Lots of similarities between the two companies - FDA has it in for both of them for who knows why.

    BTW, I was right about shortie - 9.7M covered yesterday, while another 8.5M new shorts were minted - NASDAQ shows only 2.5M were short 2 weeks ago, so there must have been multiple shorts/covers during yesterday's run - no way there were 7.2M naked shorts in this stock. Looks like profit takers like me are gone, volume way down today, as is the pps.

    P.S. 100 reps is nowhere near enough to sell Yosprala plus Tribute's products - need hundreds of them to cover the states - OREX/Takeda used 900 reps to launch Contrave for instance. Additional revs from Tribute's drugs will get Alarex to cash flow positive faster, but it's still going to take years IMO.

  • Reply to

    Thanks shortie!

    by sts_66 Jun 8, 2015 6:18 PM
    sts_66 sts_66 Jun 8, 2015 7:07 PM Flag

    D00D, I owned POZN since 2006 - a 'long" doesn't get much longer than that!

  • We had a good short squeeze this morning - from 11:15, when the halt was lifted until noon ~ 2M shares traded, almost 10x the normal daily volume - I expect shorts covered and reshorted, have to check Shortanalytics later tonight. I took the opportunity to close out my positions in 2 accounts - why? No BO coming now, no BP partner to help share costs of a sales team - it's GIA, which is VERY expensive - sales reps cost $150k to $175k/yr fully loaded (includes all overhead and benefits plus salary) - 150 reps will cost ~ $26M/yr, 300 ~ $53M, and Tribute only has 34 total employees, maybe 20-25 sales reps, so building up a sales team of reps plus managers is going to take some time and a LOT of money (see AMRN). Unless Yosprala takes the world by storm, the company will be losing money for several years at a minimum IMNSHO.

    Deerfield is buying $75 million of Aralez at a purchase price of $7.20 per ordinary share, and getting $75 million in 2.5% Convertible Senior Secured Notes due six years from issuance with a conversion price of $9.54 per ordinary share (dilution). The close on Friday was $7.52, so DF got a 4% discount. POZN shares will be swapped 1:1 for shares in Aralez, so DF believes the fair value is somewhere between $7.20 and $9.54. I've owned several bios that entered financing deals with DF, and DF is notorious for "shorting against the box" when they have warrants or convertibles in hand - that will cap the pps below $9.54 - have seen it happen every time.

    This has been dead money for years (unless you traded it), so I'll gladly take the 30% profit I got today and move on - don't forget the special $1.75 div in 2013 was ROC, and reduced your taxable basis by the same amount per share - the new deal will apparently be a taxable event too according to the PR - Uncle Sam will take some money from you - not good if you own POZN in an IRA, like I did (plus in a non-sheltered account).

    GLTA, I'm outta here! (to the delight of a few, I expect)

  • Reply to

    US$146 million

    by bgubbor Jun 8, 2015 10:56 AM
    sts_66 sts_66 Jun 8, 2015 11:41 AM Flag

    Deerfield is investing up to $350M in the combined company, getting stock for $7.20/shr - very undervalues new company IMO:

    "In connection with the acquisition, a syndicate of leading healthcare investors, led by Deerfield, has committed up to US$350 million in growth capital for the combined company, intended to support the anticipated commercial launch of YOSPRALA and for future acquisitions. Such financing is expected to close simultaneously with the closing of the transaction with Tribute. The proposed investment in Aralez includes:

    US$75 million of equity at a purchase price of US$7.20 per ordinary share;
    US$75 million in 2.5% Convertible Senior Secured Notes due six years from issuance with a conversion price of US$9.54 per ordinary share; and
    Up to US$200 million committed senior secured debt facility to fund future acquisitions.
    "This is an ideal opportunity to invest in a team, led by Adrian Adams, that knows how to foster innovation in healthcare," said James Flynn, Managing Partner at Deerfield. "On behalf of our other investors, we offer our full support and look forward to seeing real change in the market in the not-so-distant future.""

  • Reply to

    Feel it in my bones

    by capitalgains68 Jun 2, 2015 11:54 AM
    sts_66 sts_66 Jun 2, 2015 4:37 PM Flag

    I hope you're wrong about GIA - and moving to Ireland might mean they don't plan on closing up shop with a BO - wording of PR is either a ruse to boost pps (fine by me) or they're going to reboot the company and go back to drug development (not fine by me). They let the entire IR&D staff go, starting from scratch will not be cheap - partner up for Yosprala or sell the asset after approval, whenever the heck that will happen. Would really like to know what the BOD is thinking here!

  • Reply to

    Finally a fire lit under Chapel Hill

    by i_gave_at_the_orifice Jun 1, 2015 12:12 PM
    sts_66 sts_66 Jun 1, 2015 2:44 PM Flag

    What are you talking about? You just lost 10% of your ownership in POZN, we all did - in a BO, if you own a lot of shares like me, you just lost thousands of dollars of profit. Removing Platcheka didn't increase the potential value of a BO either. And if you think trying to sell PA on their own is a good idea, you haven't witnessed how it crushed other biotechs like I have.

  • Reply to

    POZEN Announces Retirement of Founder,

    by nowagron Jun 1, 2015 7:14 AM
    sts_66 sts_66 Jun 1, 2015 11:56 AM Flag

    OMG. If they GIA for PA franchise it's going to be a disaster.....seen it happen to other small bios.....POZN hacked to the bone for BO and/or partner, not to GIA! Giving away 10% of the company means they had a hard time hiring replacement execs too. #$%$!

  • Reply to

    wow

    by gkas711 Apr 27, 2015 2:16 PM
    sts_66 sts_66 Apr 27, 2015 4:09 PM Flag

    I wasn't even aware GSFVF still had operations - thought they went bankrupt? Do old shareholders like me have any chance of recovering a dime?

  • Reply to

    wow

    by gkas711 Apr 27, 2015 2:16 PM
    sts_66 sts_66 Apr 27, 2015 3:07 PM Flag

    I just noticed the volume myself - who on earth is trading that much stock, even if it is nearly worthless? Only thing I can find is that CHK signed a deal with them in March to drill a test well?

  • Chip stocks slump after TI, Xilinx, Qualcomm offer soft guidance • 12:20 PM
    Eric Jhonsa, SA News Editor

    " While the Nasdaq is up 0.3%, chip stocks are selling off (SOXX -1.8%) after Texas Instruments, Xilinx, and Qualcomm all provided soft calendar Q2 guidance. TI and Xilinx also missed Q1 sales estimates, while Qualcomm beat........ Qualcomm largely blamed its guidance on the iPhone 6's share gains and a loss of chip share at Samsung, rather than industry demand issues.

  • Despite all efforts by JPM and various SA bashers, BPT comes back (again), just as I predicted on SA - shook the tree of lots of retail, then they scooped up the lower priced shares. Don't fall for their BS!

  • Reply to

    Normal price action

    by mpk52351 Apr 14, 2015 10:57 AM
    sts_66 sts_66 Apr 14, 2015 12:30 PM Flag

    Almost all chipmakers, anyone making parts for PCs and phones, are down since SanDisk warned of a Q1 miss on March 27, also suffering from strong US dollar. QRVO shot way too high too fast anyway - was one of the largest gainers over 2014-2015. Earnings likely to blow away estimates, shorts have been using this downtrend to cover - check Shortanalytics to see what I mean.

  • Reply to

    No word on Q1 distribution?

    by sts_66 Apr 6, 2015 3:08 PM
    sts_66 sts_66 Apr 7, 2015 10:57 AM Flag

    And the stock doesn't tank today - which means all the SA bashers failed, JPM failed, to crash the stock low enough to cover their shorts or buy it low for clients.

  • BPT usually announces on April 4th - almost COB today and nothing from them yet?

TSRA
36.89-0.86(-2.28%)12:10 PMEDT